Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Meribank Biotech Co., Ltd (4724.TWO)

Compare
14.80
-0.25
(-1.66%)
At close: 2:59:45 PM GMT+8
Loading Chart for 4724.TWO
  • Previous Close 15.05
  • Open 15.05
  • Bid 14.65 x --
  • Ask 14.80 x --
  • Day's Range 14.65 - 15.05
  • 52 Week Range 13.90 - 46.30
  • Volume 114,701
  • Avg. Volume 187,035
  • Market Cap (intraday) 1.416B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.19
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the storage of placental umbilical cord mesenchymal stem cells, cord blood hematopoietic stem cells, and immune cells. It also provides cell cryopreservation services. Meribank Biotech Co., Ltd was founded in 2013 and is based in Taipei City, Taiwan.

www.meribank.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4724.TWO

View More

Performance Overview: 4724.TWO

Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4724.TWO
47.14%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
17.06%

1-Year Return

4724.TWO
60.85%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.16%

3-Year Return

4724.TWO
54.04%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
11.55%

5-Year Return

4724.TWO
54.04%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
85.71%

Compare To: 4724.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4724.TWO

View More

Valuation Measures

Annual
As of 4/18/2025
  • Market Cap

    1.44B

  • Enterprise Value

    2.22B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.93

  • Price/Book (mrq)

    1.19

  • Enterprise Value/Revenue

    6.05

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -25.85%

  • Return on Assets (ttm)

    -2.93%

  • Return on Equity (ttm)

    -10.27%

  • Revenue (ttm)

    366.43M

  • Net Income Avi to Common (ttm)

    -94.71M

  • Diluted EPS (ttm)

    -1.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    165.09M

  • Total Debt/Equity (mrq)

    77.45%

  • Levered Free Cash Flow (ttm)

    -330.4M

Research Analysis: 4724.TWO

View More

Company Insights: 4724.TWO

Research Reports: 4724.TWO

View More